Document:

EX-10.14

 Exhibit 10.14 

RIGHT OF FIRST REFUSAL AGREEMENT 

THIS RIGHT OF FIRST REFUSAL AGREEMENT dated as of the dates set forth below, between Kilpatrick Partners, L.L.C., an Oklahoma limited
liability company (“Seller”), and Paycom Payroll, LLC, a Delaware limited liability company (“Buyer”). 
 WHEREAS,
Seller is currently the owner of approximately 90.25 acres, more or less, located in the Southwest Quarter (SW/4) of Section Eight (8), Township Thirteen (13) North, Range Four (4) West of the Indian Meridian, Oklahoma City, Oklahoma
County, Oklahoma; 
 WHEREAS, Seller is currently under contract with Buyer to sell approximately eighteen of Seller’s 90.25 acres to
Buyer, leaving Seller with a remaining approximately 72 acres in said SW/4 of Section Eight (8). 
 WHEREAS, Seller desires to grant to
Buyer a right of first refusal for a certain portion of Seller’s remaining 72 acres in said SW/4 of Section Eight (8); 
 WHEREAS, the
right of first refusal provided to Buyer herein shall be for 28.1052 acres, more or less, and located in the Southwest Quarter (SW/4) of Section Eight (8), Township Thirteen (13) North, Range Four (4) West of the Indian Meridian, Oklahoma
City, Oklahoma County Oklahoma County, Oklahoma, and more particularly described on Exhibit “A” attached hereto as a part hereof (the “Property”). 

WHEREAS, the right of first refusal granted herein shall be for a period of twenty (20) years beginning on October 4, 2013 and
expiring at 5:00 p.m., CST, on the October 3, 2033 (“Right of First Refusal Period”), and on the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the sum of Five Hundred Dollars ($500.00) in hand paid by Buyer to Seller and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. If, at any time after the
date of this Agreement and during the Right of First Refusal Period, Seller shall desire to offer to sell the Property or any part thereof, or shall receive from a third party a bona fide offer to purchase the Property or any part thereof
which Seller desires to accept, Seller, before making or accepting the offer, as the case may be, shall send Buyer two (2) copies of a contract for the sale of the Property embodying the terms of the offer, both copies of which have been duly
executed by Seller, together with a written notification from Seller of Seller’s intention to make or accept the offer embodied in the contract, as the case may be, if the offer is not accepted by Buyer. Buyer shall have the right, within ten
(10) calendar days of the receipt of the contract and the written notice, to purchase the Property or such part thereof on the terms and conditions set forth in the contract. In the event Buyer elects to accept the offer embodied in the
contract, Buyer must do so by executing one copy of the contract and returning it to Seller within the ten (10) calendar day period. The contract provided to Buyer shall provide Buyer with a reasonable time for Buyer to comply with the purchase
contract, customary title work, and/or customary financing for purposes of consummating a sale. The offer provided to Buyer for Buyer’s consideration herein may include all or any portion of the Property, but may not include any additional
property. 
 2. If Buyer does not accept the offer embodied in the contract within the ten (10) calendar day period provided in Paragraph 1
hereof, then the offer embodied in the contract shall be deemed rejected and Seller shall be free for a period of six (6) months from the expiration of the 

 
ten (10) calendar day period to sell the Property or such part thereof to third parties on the same terms set forth in the purchase contract tendered to Buyer. In the event the Property or
such part thereof is not sold to a third party within the six (6) month period, then any further offer to sell or to purchase the Property or any part thereof must first be submitted to Buyer in accordance with the provisions of Paragraph 1.

 3. Seller shall not sell or exchange the Property, or any portion thereof, nor shall Seller enter into any sale, option, exchange or
trade agreement concerning the Property for the duration of the Right of First Refusal Period without first complying with the Right of First Refusal provided to Buyer herein. 

4. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective personal representatives, heirs
and assigns. 
 5. All notices pursuant to this Agreement shall be deemed given when personally delivered to the party to whom it is
directed or in lieu of personal delivery on the third business day after the same is deposited in the United States mail, postage prepaid, sent Certified Mail, Return Receipt Requested, addressed as follows: 

 

			
	If to Seller:	  	Chad Richison, Manager
		  	Kilpatrick Partners, L.L.C.
		  	7501 W. Memorial Road
		  	Oklahoma City, OK 73142
		  	Telephone Number: 405-722-6900
		
	If to Purchaser:	  	Craig Boelte, CFO
		  	Paycom Payroll, LLC
		  	7501 W. Memorial Road
		  	Oklahoma City, OK 73142
		  	Telephone Number: 405-722-6900
		
	 with a copy to:
	  	John Falcone, Esq.
		  	Cheek & Falcone, PLLC
		  	6301 Waterford Blvd, Suite 320
		  	Oklahoma City, OK 73118
		  	Telephone Number: (405) 286-9191

 Either party may change her or their address for the purposes of this section by giving notice of the changed address to the
other party in the manner provided for above. 
 6. Covenant Running with the Land; Survival and Termination. The parties intend that this
Right of First Refusal be a covenant running with the land until such time as it is expired or terminated pursuant to its terms. This Right of First Refusal shall survive any transfer or disposition of the Property not made in strict accordance with
the terms of this Right of First Refusal. This Right of First Refusal shall terminate upon any of the following events: (1) A transfer to a third party that occurs subsequent to strict compliance with the terms hereof; (2) Buyer purchases
the land and takes title to the Property from Seller; and (3) expiration of the twenty year Right of First Refusal Period. This Agreement may be enforced through specific performance against any party or any person, including against any
third-party purchaser of the Property. 

 7. Recording. The Buyer may record this Agreement in the Oklahoma County Clerk’s Office.

 8. Prevailing Party Attorney’s Fees. In the event of any litigation arising out of this Agreement, the court shall award
attorney’s fees and costs to the prevailing party. 
 9. Time is of the essence with respect to the obligations of this Right of First
Refusal. 
 10. This agreement shall be governed by and construed in accordance with the Laws of the State of Oklahoma. Venue for any
litigation arising out of this agreement shall exclusively be in Oklahoma County District Court or the federal courts located in Oklahoma County, Oklahoma. 

EXECUTED in Oklahoma County, Oklahoma as of the dates set forth herein. 

 

			
	SELLER:
	
	 Kilpatrick Partners, L.L.C.
 an
Oklahoma limited liability company

	
	/s/ Chad Richison
	By:	 	Chad Richison, Sole Manager
	
	BUYER:
	
	 Paycom Payroll, LLC
 a Delaware
limited liability company

	
	/s/ Craig E. Boelte
	By:	 	Craig E. Boelte, CFO

 ACKNOWLEDGMENT 

 

			
	STATE OF OKLAHOMA	  	
	 	  	ss.
	COUNTY OF OKLAHOMA	  	

 Before me, a Notary Public in and for said county and state, on this 31 day of October, 2013, personally
appeared Chad Richison, to me known to be the identical person who executed the within and foregoing instrument, and acknowledged to me that he executed the same in his capacity as sole manager of Kilpatrick Partners, L.L.C. as his free and
voluntary act and deed for the uses and purposes therein set forth. 
 Given under my hand and seal of office the day and year last above
written. 
  

	
	/s/ Londa Jackson
	
	NOTARY PUBLIC

  

			
	My Commission (1.7.17) Expires:
		
	 	 	
	{SEAL}	 	

 ACKNOWLEDGMENT 
  

			
	STATE OF OKLAHOMA	  	
	 	  	ss.
	COUNTY OF OKLAHOMA	  	

 Before me, a Notary Public in and for said county and state, on this 31 day of October, 2013, personally
appeared Craig E. Boelte, to me known to be the identical person who executed the within and foregoing instrument, and acknowledged to me that he executed the same in his capacity as an officer of Paycom Payroll, LLC, as his free and voluntary act
and deed for the uses and purposes therein set forth. 
 Given under my hand and seal of office the day and year last above written. 

 

	
	/s/ Londa Jackson
	
	NOTARY PUBLIC

  

			
	My Commission (1.7.17) Expires:
		
	 	 	
	{SEAL}	 	

 EXHIBIT A 

LEGAL DESCRIPTION 
 Paycom 

Right of First Refusal Tract 

October 4, 2013 
 A tract of land being a
part of the Southwest Quarter (SW/4) of Section Eight (8), Township Thirteen (13) North, Range Four (4) West of the Indian Meridian, Oklahoma City, Oklahoma County, Oklahoma, being more particularly described as follows: 

Commencing at the Southeast (SE) Corner of said Southwest Quarter (SW/4); 

THENCE North 00°15’38” West (North 00°15’26” West record), along and with the East line of said Southwest Quarter (SW/4), a
distance of 575.51 feet (575.66 feet record) to the Southeast (SE) Corner of Paycom recorded in Book PL68, Page 95; 
 THENCE North 88°41’40”
West (North 88°42’11” West record), along and with the North line of a tract of land owned by the Oklahoma Turnpike Authority recorded in Book 7536, Page 339, a distance of 701.75 feet (701.77 feet record); 

THENCE North 86°46’27” West (North 86°48’46” West record), continuing along and with the North line of a tract of land owned by
the Oklahoma Turnpike Authority recorded in Book 7536, Page 339, a distance of 360.72 feet to the POINT OF BEGINNING; 
 THENCE continuing North
86°46’27” West (North 86°48’46” West record), continuing along and with the North line of a tract of land owned by the Oklahoma Turnpike Authority recorded in Book 7536, Page 339, a distance of 590.10 feet; 

THENCE North 89°18’20” West (North 89°16’40” West record), a distance of 414.86 feet; 

THENCE North 41°55’58” East, departing said North line, a distance of 73.71 feet; 

THENCE North 20°28’18” East, a distance of 146.45 feet; 

THENCE North 69°30’50” East, a distance of 145.55 feet; 

THENCE North 55°45’38” West, a distance of 156.20 feet; 

THENCE North 31°39’05” West, a distance of 66.47 feet; 

THENCE North 43°53’25” East, a distance of 131.44 feet; 

THENCE North 03°42’36” East, a distance of 75.07 feet; 

THENCE North 72°07’33” East, a distance of 196.23 feet; 

THENCE North 76°22’07” East, a distance of 114.52 feet; 

Prepared by Johnson & Associates, Inc. (Matthew Johnson P.L.S. 1807) 

 THENCE North 34°28’59” East, a distance of 58.54 feet; 

THENCE North 09°01’16” West, a distance of 28.69 feet; 

THENCE South 69°52’47” West, a distance of 76.44 feet; 

THENCE North 29°37’44” West, a distance of 126.29 feet; 

THENCE North 67°46’08” West, a distance of 45.70 feet; 

THENCE North 12°25’23” West, a distance of 88.87 feet; 

THENCE North 11°42’22” East, a distance of 68.13 feet; 

THENCE North 25°43’48” West, a distance of 155.34 feet; 

THENCE North 00°24’28” West, a distance of 93.73 feet; 

THENCE North 74°18’20” East, a distance of 94.17 feet; 

THENCE South 89°52’02” East, a distance of 147.01 feet; 

THENCE North 28°46’21” East, a distance of 99.56 feet; 

THENCE North 02°16’36” West, a distance of 82.41 feet; 

THENCE North 07°35’57” East, a distance of 80.45 feet; 

THENCE North 43°23’45” West, a distance of 61.34 feet; 

THENCE North 14°11’54” East, a distance of 91.73 feet; 

THENCE North 68°59’55” East, a distance of 84.79 feet; 

THENCE North 88°04’19” East, a distance of 104.71 feet; 

THENCE North 58°36’11” East, a distance of 200.30 feet; 

THENCE North 43°45’26” East, a distance of 87.00 feet; 

THENCE North 01°24’55” East, a distance of 52.84 feet; 

THENCE North 66°42’12” West, a distance of 133.57 feet; 

THENCE North 07o27’53” West, a distance of 60.72 feet; 

THENCE North 38°46’55” West, a distance of 18.39 feet to a point on the North line of said Southwest Quarter (SW/4); 

Prepared by Johnson & Associates, Inc. (Matthew Johnson P.L.S. 1807) 

 THENCE South 89°52’18” East, along and with the North line of said Southwest Quarter (SW/4), a
distance of 210.08 feet; 
 THENCE South 00°01’27” East, departing said North line, a distance of 2,035.89 feet to the POINT OF BEGINNING.

 Containing 1,224,264 square feet or 28.1052 acres, more or less. 

Basis of Bearing: The East line of the SW/4 of Section 8, T13N, R4W having an assumed bearing of North 00°15’38” West. 

Prepared by Johnson & Associates, Inc. (Matthew Johnson P.L.S. 1807)EX-10.10

 Exhibit 10.10 

EXECUTION COPY 
 AMENDED 11/18/13

 April 27, 2012 
 Dr. Y.S Babu 

4836 Southlake Parkway 
 Birmingham, AL 35244 

babu@biocryst.com 
 Dear Dr. Babu: 

On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst” or the “Company”), we are pleased to
extend this employment agreement to you as Senior Vice President Drug Discovery We, along with the other members of the Company’s Board of Directors (the “Board”), and the Company’s management team, continue to be very impressed
with you and what you bring to the Company. We believe that with your background, you will continue to make significant contributions to the success of the Company. 

This letter agreement (the “Agreement”) will serve to confirm our agreement with respect to the terms and conditions of your
employment. 
 1. Term of Employment. Subject to the terms and conditions of this Agreement, BioCryst hereby employs Dr. Y.S. Babu (the
“Employee”), with an effective hire date of January 1, 1988 as Senior Vice President Drug Discovery . Employee shall maintain employment at the Company’s Birmingham, Alabama office. The Employee shall not, during the term of his
employment, engage in any other business activity that would interfere with, or prevent him from carrying out, his duties and responsibilities under this Agreement. BioCryst hereby agrees and acknowledges that any compensation which the Employee
receives from participation in such allowable activities shall be outside the scope of this Agreement and in addition to any compensation received hereunder. The term of employment of Employee under this Agreement shall commence as of April 27,
2012, and shall terminate on April 27, 2015 unless earlier terminated in accordance with the provisions of paragraph 4 hereof. In the event Employee is retained by the Company as Senior Vice President Drug Discovery past April 27,
2015, the terms of his employment shall continue to be governed by this Agreement unless otherwise provided by the Board. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 2
 
  

 2. Basic Full-Time Compensation and Benefits. 

(a) As basic compensation for services rendered under this Agreement, Employee shall be entitled to receive from BioCryst, a
salary of $27,628.33 per month ($331,540 per annum) payable in bi-monthly payments for each calendar month during the term of this Agreement, beginning March 1, 2012. This salary will be reviewed annually by the Board of Directors and may be
raised at the discretion of the Board. 
 (b) In addition to the basic compensation set forth in (a) above, Employee
shall be eligible to earn a cash bonus, payable as soon as reasonably practicable in the calendar year following each calendar year during the term of this Agreement, based on the Company’s achievement of performance related goals proposed by
management and approved by the Board for the Company’s applicable fiscal year (the “Fiscal Year”). The bonus actually earned, if any, shall be based on a target amount equal to 30% of the base compensation earned by executive during
such Fiscal Year (the “Target Amount”), and shall be pro-rated based on the degree to which the performance goals have been achieved, subject to a minimum level of achievement proposed by management and approved by the Board. The Target
Amount for the 2012 Fiscal Year shall be prorated based on Employee’s base compensation earned during 2012. The Board may, in its discretion, approve a bonus in excess of the Target Amount if the performance goals have been exceeded. Employee
must be employed through April 1, of the next succeeding Fiscal Year in order to receive the annual bonus for each Fiscal Year. 

(c) In addition to the basic compensation set forth in (a) and (b) above, Employee shall be entitled to receive such
other benefits and perquisites provided to other executive officers of BioCryst which benefits may include, without limitation, reasonable vacation (currently 5 weeks), sick leave, medical benefits, life insurance, and participation in profit
sharing or retirement plans. 
 (d) In addition to the compensation set forth in paragraphs 2(a), (b) and
(c) above, the Board of Directors of BioCryst may from time to time, in its discretion, also grant such other cash or stock bonuses to the Employee either as an award or as an incentive as it shall deem desirable or appropriate. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 3
 
  

 3. Performance Based Equity Awards. 

In connection with Employee’s execution of this Agreement, Employee shall be eligible for equity incentive awards as follows: 

(a) As part of the BioCryst Pharmaceuticals Performance Management & Compensation Planning program, you will be
eligible for additional long term equity awards (mix of stock options and restricted stock awards). The actual equity award pool will be determined each year, with individual equity awards based on Employee performance assessment and results against
individual objectives. All equity awards will reflect the specific guidelines of the program, are subject to approval each year by the Compensation Committee of the Board and subject to the requirements of state and federal laws. 

(b) The parties intend for the Option to qualify as “incentive stock options,” as that term is defined in
Section 422 of the Internal Revenue Code of 1986, as amended (“Section 422”) to the fullest extent possible. The parties understand that the portion of the Option, together with the portion of any other incentive stock option granted
by BioCryst and its parent and subsidiary corporations, if any, which may become exercisable in any year in excess of an aggregate of $100,000 fair market value, determined as of the date the Option or such other Option, as the case may be, was
granted, and may not be treated as an incentive stock option under Section 422. 
 (c) The award set forth in paragraph
3(a) above will vest, contingent on Employee’s continued provision of services to the Company on each respective vesting date, over a period of 4 years as follows: The Option will initially become exercisable for 25% of the Optioned Shares upon
Optionee’s completion of twelve (12) months of Service (as defined in the Standard Stock Option Agreement) measured from the Grant Date and will become exercisable for the balance of the Optioned Shares at the rate of 25% of the Optioned
Shares upon Optionee’s completion of each additional year of Service measured from the first anniversary of the Grant Date for the following three years until fully vested on the fourth anniversary of the grant. 

(d) The stock option and restricted stock awards set forth in paragraph 3(a ) above shall be granted under and subject to the
terms of the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (the “Stock Incentive Plan”). All awards shall be subject to the terms of specific award agreements between the Employee and the Company, which Employee will be required to
execute as a condition of the grants. 
 4. Termination. 

(a) If Employee’s employment is terminated as a result of (i) the expiration of the stated term of this Agreement,
(ii) the Employee’s resignation, (iii) the Employee’s death, (iv) by the Company for Cause, or (v) by the Company as a result of Disability, Employee will receive base salary, as well as any accrued but unused vacation
(if applicable) and other compensation, earned through the effective termination date, and no additional compensation, except as set forth in Section 4(d) below. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 4
 
  

 For all purposes under this Agreement, a termination for “Cause”
shall mean a determination by the Board that Employee’s employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Company;
(ii) a violation of a federal or state law or regulation applicable to the business of the Company; (iii) conviction or plea of no contest to a felony under the laws of the United States or any State; (iv) fraud or misappropriation of
property belonging to the Company or its affiliates; (v) a breach in any material respect of the terms of any confidentiality, invention assignment or proprietary information agreement with the Company or with a former employer,
(vi) failure to satisfactorily perform Employee’s duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) misconduct or gross negligence in connection with the
performance of Employee’s duties. 
 “Disability” shall mean the inability of Employee to perform his duties
hereunder by reason of physical or mental incapacity for ninety (90) days, whether consecutive or not, during any consecutive twelve (12) month period. 

(b) If the Company terminates Employee’s employment without Cause, it shall provide written notice of termination to
Employee, along with any base salary and accrued but unused vacation or other compensation earned through the effective termination date, and, conditioned on Employee (a) signing and not revoking a release of any and all claims, in a form
prescribed by the Company, and (b) returning to the Company all of its property and confidential information that is in Employee’s possession, Employee will receive the following: (i) continuation of base salary for 1 year beyond the
effective termination date, payable in accordance with the regular payroll practices of the Company; and (ii) if Employee elects to continue health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(“COBRA”) following termination of employment, the Company shall pay the monthly premium under COBRA until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which Employee commences
employment with an entity other than the Company. Employee will notify the Company in writing within 5 days of your receipt of an offer of employment with any entity other than the Company, and will accordingly identify the date upon which you will
commence employment in such writing. 
 (c) If, during Employee’s employment with the Company, there is a Change of
Control, all equity awards granted to Employee under paragraph 3 and otherwise shall vest in full. In addition, if the Company terminates Employee’s employment without Cause or Employee is Constructively Terminated within 6 months of the Change
in Control, then Employee will be eligible to receive the benefits provided in paragraph 4(b), under the terms and conditions set forth in that paragraph. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 5
 
  

 “Change of Control” shall be defined as (i) a merger or
consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the State of the Company’s incorporation; (ii) the sale, transfer or other disposition of all or
substantially all of the assets of the Company in liquidation or dissolution of the Company; (iii) any reverse merger in which the Company is the surviving entity but in which securities possessing more than fifty percent (50%) of the
total combined voting power of the Company’s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such merger; (iv) any person or related group of persons
(other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of
securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s stockholders; or (v) a change in
the composition of the Board over a period of twenty-four (24) consecutive months or less such that a majority of the Board members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership,
to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least two-thirds of the
Board members described in clause (A) who were still in office at the time such election or nomination was approved by the Board. 

“Constructive Termination” shall mean a resignation of employment within 30 days of the occurrence of any of the
following events which occurs within 6 months following a Change of Control: (i) a material reduction in Employee’s responsibilities; (ii) a material reduction in Employee’s base salary, unless such reduction is comparable in
percentage to, and is part of, a reduction in the base salary of all executive officers of the Company; or (iii) a relocation of Employee’s principal office to a location more than 50 miles from the location of Employee’s principal
office immediately preceding a Change of Control. 
 (d) If (i) Employee remains an employee of the Company after the
expiration of the three year term of this Agreement; and (ii) within 6 months thereafter, Employee resigns as a result of a material and adverse change in the Company’s business, then Employee shall be entitled to receive the severance
benefits on the terms and conditions specified in paragraph 4(b) above. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 6
 
  

 (e) In the event (i) any payments described in paragraphs 4(b),
(c) or (d) above would be “deferred compensation” subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”); and (ii) Employee is a “specified employee” (as defined in
Code Section 409A(2)(B)(i)), such payments shall, to the extent required by Code Section 409A, be delayed for the minimum period and in the minimum manner necessary to avoid the imposition of the tax required by Code Section 409A.

 5. Non-Competition; Proprietary Information and Inventions. 

(a) Proprietary Information and Inventions Agreement. As a condition precedent to the employment of Employee by the
Company, Employee shall execute the Company’s standard Proprietary Information and Inventions Agreement, attached hereto as Exhibit A. 

(b) Non-Competition Agreement. The Employee agrees that for one (1) year following the termination of this
Agreement by reason of the voluntary termination by the Employee, without cause on the part of BioCryst, the Employee shall not become the Vice President Drug Discovery or become a key executive of another for-profit business enterprise whose
activities are at such time directly competitive with BioCryst. 
 (c) Equitable Remedies. Employee acknowledges and
recognizes that a violation of this paragraph by Employee may cause irreparable and substantial damage and harm to BioCryst or its affiliates, could constitute a failure of consideration, and that money damages will not provide a full remedy for
BioCryst for such violations. Employee agrees that in the event of his breach of this paragraph, BioCryst will be entitled, if it so elects, to institute and prosecute proceedings at law or in equity to obtain damages with respect to such breach, to
enforce the specific performance of this paragraph by Employee, and to enjoin Employee from engaging in any activity in violation hereof. 
 6.
Miscellaneous. 
 (a) Entire Agreement. This Agreement, including the exhibits hereto, constitutes the entire
agreement between the parties relating to the employment of the Employee by BioCryst and there are no terms relating to such employment other than those contained in this Agreement. No modification or variation hereof shall be deemed valid unless in
writing and signed by the parties hereto. No waiver by either party of any provision or condition of this Agreement shall be deemed a waiver of similar or dissimilar provisions or conditions at any time. 

(b) Assignability. This Agreement may not be assigned without prior written consent of the parties hereto. To the extent
allowable pursuant to this Agreement, this 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 7
 
  

 
Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective executors, administrators, personal representatives, heirs, successors and
assigns. 
 (c) Notices. Any notice or other communication given or rendered hereunder by any party hereto shall be in
writing and delivered personally or sent by registered or certified mail, postage prepaid, at the respective addresses of the parties hereto as set forth below. 

(d) Captions. The section headings contained herein are inserted only as a matter of convenience and reference and in no
way define, limit or describe the scope of this Agreement or the intent of any provision hereof. 
 (e) Taxes. All
amounts to be paid to Employee hereunder are in the nature of compensation for Employee’s employment by BioCryst, and shall be subject to withholding, income, occupation and payroll taxes and other charges applicable to such compensation. 

(f) Governing Law. This Agreement is made and shall be governed by and construed in accordance with the laws of the
State of Alabama without respect to its conflicts of law principles. 
 (g) Date. This Agreement is dated as of
April 27, 2012. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 8
 
  

 If the foregoing correctly sets forth our understanding, please signify your acceptance of
such terms by executing this Agreement, thereby signifying your assent, as indicated below. 
  

			
	Yours very truly,
	
	BIOCRYST PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jon Stonehouse

		 	Jon Stonehouse
		 	Chief Executive Officer

 
			
		
	Address:	 	
	
	 4505 Emperor Blvd., Suite 200

Durham, NC 27703

	
	AMENDED, AGREED AND ACCEPTED, as of this 18th day of November, 2013.
	
	 /s/ Y.S. Babu

	Y.S. Babu
		
	Address:	 	
	
	 4836 Southlake Parkway
 Birmingham,
AL 35244

 EXECUTION COPY 

Exhibit A 
 (Proprietary
Information and Inventions Agreement) 
 EMPLOYEE’S PROPRIETARY INFORMATION AND INVENTIONS 

AGREEMENT 
 I, Dr. Y.S. Babu, recognize that
BioCryst Pharmaceuticals, Inc., a Delaware corporation (hereinafter the “Company”, is engaged in a continuous program of research, development, and product; on respecting its business, present and future, including fields generally related
to its business. 
 I understand that: 
 A. As
part of my employment by the Company I will faithfully and diligently serve and endeavor to further and safeguard the interests of the Company and I recognize that I am expected to make new contributions and inventions of value to the Company; 

B. My employment creates a relationship of confidence and trust between me and the Company with respect to any information: 

1. Applicable to the business of the Company: or 

2. Applicable to the business of any client or customer of the Company which may be made known to me by the Company or by any client or
customer of Company or learned by me during the period of my employment. 
 C. The Company possesses and will continue to possess information that has been
created, discovered, developed, or otherwise become known to the Company (including without limitation information created, discovered, developed, or made known by me during the period of or arising out of my employment by the Company) and/or in
which property rights have been assigned or otherwise conveyed to the Company, which information has commercial value in the business in which the Company is or may be engaged. All of the aforementioned information is hereinafter called
“Proprietary Information.” By way of illustration, but not limitation Proprietary Information includes trade secrets, processes, formulas, data and know-how, improvements, inventions, techniques, marketing plans, strategies, forecasts, and
customer lists. 
 In consideration of my employment or continued employment, as the case may be, by the Company and the compensation
received by me from the Company from time to time. I hereby agree as follows: 
 1. All Proprietary Information shall be the sole property of the Company
and its assigns, and the Company and its assigns shall be the sole owner of all patents and other rights, title and interest in connection therewith. I hereby assign to the Company any and all rights I may have or acquire in such Proprietary
Information and/or patents. At all times, both during my employment by the Company and after its termination, I will keep in confidence and trust all Proprietary Information, and I will not use or disclose any Proprietary Information or anything
relating to it without the prior written consent of the Company, except as may be necessary in the ordinary course of performing my duties as an employee of the Company. 

2. I agree that, during the period of my employment by the Company, I will not, without the Company’s express prior written consent, engage in any
employment or consulting other than for the Company. In the event of the termination of my employment by me or by the Company for any reason, I will promptly deliver to the Company all documents and data of any nature pertaining to my work with the
Company and I will not take with me any documents or data of any description or any reproduction of any description containing or pertaining to any Proprietary Information. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 10
 
  

 3. I will promptly and fully disclose to the Company, or any persons designated by it, all improvements,
inventions, formulas, processes, techniques, know-how, and data, whether or not patentable, copyrightable, or otherwise protectible as property, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during
the period of my employment by the Company which are related to or useful in the business of the Company, or result from tasks assigned me by the Company or result from use of premises owned, leased, or contracted for by the Company (all said
improvements, inventions, formulas, processes, techniques, know-how, and data shall be collectively hereinafter called “Inventions”). I agree to keep complete, accurate, and authentic accounts, notes, data, and records of all Inventions in
the manner and form requested by the Company, which accounts, notes, data, and records shall be and remain the sole property of the Company. I agree to surrender the same promptly to the Company upon its request or, in the absence of such a request,
upon the termination of my employment by the Company. 
 4. I agree that all Inventions are and shall be the sole property of the Company and its assigns,
and that the Company and its assigns shall be the sole owner of all patents and other rights in connection therewith. I hereby assign to the Company any and all rights I may have or acquire in or to such Inventions and patents. I further agree as to
all such Inventions to assist the Company in every proper way (but at the Company’s expense) to obtain and from time to time enforce patents, including amendments, extensions, and continuations of said patents on said Inventions in any and all
countries, and to that end I will execute all documents for use in applying for and for obtaining such patents, amendments, extensions, and continuations and enforcing same, as the Company may desire, together with any assignments thereof to the
Company or persons designated by it. My obligation to assist the Company in obtaining and enforcing patents, amendments, extensions, and continuations for such Inventions in any and all countries shall continue beyond the termination of my
employment, but the Company shall compensate me at a reasonable rate after such termination for time actually spent by me at the Company’s request on such assistance. 

5. As a matter of record I attach hereto a complete list of all Inventions or improvements relevant to the subject matter of my employment by the Company
which have been conceived, made, or reduced to practice by me, alone or jointly with others, prior to my engagement by the Company which I desire to remove from the operation of this Agreement. I covenant that such list is complete. If no such list
is attached to this Agreement, I represent that I have no such Inventions and improvements at the time of signing this Agreement. 
 6. I represent that my
performance of all of the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence Proprietary Information acquired by me in confidence or in trust prior to my employment by the
Company. I have not entered into, and I agree that I will not enter into, any agreement either written or oral, in conflict herewith. 
 7. I understand
that, as part of the consideration of the offer of employment extended to me by the Company or of my continued employment by the Company, as the case may be, I will not bring, have not brought, with me to the Company and I will not use, have not
used, in the performance of my responsibilities at the Company, materials or documents of a former employer, unless I have obtained written authorization from the former employer for their possession and use. Accordingly, this is to advise the
Company that the only materials that I will bring to the Company or use in my employment are identified on the attached sheet (Exhibit A) and, as to each such item, I represent that I have obtained, prior to the effective date of my employment with
the Company, written authorization for their possession and use in my employment with the Company. I also understand that, in my employment with the Company. I am not to breach any obligation of confidentiality that I have to former employers, and I
agree that I shall fulfill all such obligations during my employment with the Company. 

 Dr. Y.S. Babu 

April 27, 2012 
  Page
 11
 
  

 8. This Agreement shall be effective as of the first day of my employment by the Company, namely: January 1,
1988. I understand and agree that this Agreement is not a contract of employment and that my employment by the Company is, for all purposes, “at will.” 

9. This Agreement shall be binding upon me, my heirs, executors, assigns, administrators, and other legal representatives and shall inure to the benefit of
the Company, its successors and assigns. 
  

									
	DATED:	 	  
	 		 	Employee:	 	  

				
	ACCEPTED AND AGREED TO:	 		 		 	
				
	BIOCRYST PHARMACEUTICALS, INC.	 		 		 	
					
	BY:	 	  
	 		 		 	
	AS ITS: Vice President of Human Resources	 		 		 	
					
	Dated:	 	  
	 		 		 	
				
	BioCryst Pharmaceuticals, Inc.	 		 		 	
	4505 Emperor Blvd., Suite 200	 		 		 	
	Durham, NC 27703	 		 		 	

 Dear Sir: 
 I
                    propose to bring to my BioCryst employment the following tangible materials and previously unpublished documents, which materials
and documents may be used in my BioCryst employment: 
  

					
	     No materials	  	    See below	  	    Additional sheets attached

 The signature below by a representative of my current or former employer confirms that my continued possession and use of
these materials is authorized. 
  

			
	AUTHORIZATION:
	
	  

	Signature
	Title:	 	  

	
	  

	Employer

  

	
	  

	Employee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]